全球糖尿病笔市场规模（按地区、范围和预测）

糖尿病笔的市场规模与预测

2024 年糖尿病笔市场规模价值 165.2 亿美元，预计到 2031 年将达到 293.5 亿美元，2024 年至 2031 年的复合年增长率为 7.45%。糖尿病笔是一种医疗设备，可让您准确、方便地註射胰岛素和其他糖尿病药物。它通常由一支装有胰岛素或药物的笔形注射器和一根一次性针头组成。使用者用笔选择所需剂量，然后皮下注射药物。糖尿病患者通常使用糖尿病笔进行日常胰岛素治疗，因为它们使用方便、剂量准确、便于携带。糖尿病笔的目的是透过使注射过程比标准注射器更容易使用、更少麻烦来简化糖尿病治疗。

糖尿病笔前景广阔，目前正在进行的开发重点是提高其功能性和易用性。智慧笔配备数位技术，可以测量胰岛素剂量并向使用者和医疗保健提供者提供即时数据，从而提供更好的糖尿病护理。

无针注射方法的研究和胰岛素配方的进步可能会提高患者的舒适度和依从性。具有客製化功能和与数位健康系统连接能力的笔的开发有可能进一步改变糖尿病护理，使其更加个人化和高效。随着糖尿病变得越来越普遍，这些发展可能会在更好地控製糖尿病方面发挥重要作用。

全球糖尿病笔市场动态

影响全球糖尿病笔市场的关键市场动态

主要市场驱动因子

糖尿病盛行率不断上升：

糖尿病笔市场受糖尿病盛行率上升的影响。国际糖尿病联盟（IDF）估计，2021年约有5.37亿成年人（20-79岁）将患有糖尿病。预计到 2030 年这一数字将增长到 6.43 亿，到 2045 年将增长到 7.83 亿。

对自我管理设备的需求不断增加：

糖尿病笔由于其方便和易用而变得越来越受欢迎。根据《糖尿病科学与技术杂誌》发表的一项调查，71% 的患者选择使用胰岛素笔而不是胰岛素瓶或註射胰岛素，声称这样可以提高生活品质和治疗满意度。

增加医疗支出：

医疗保健支出的增加，尤其是在发展中国家，正在推动糖尿病笔市场的发展。世界卫生组织（WHO）预计，2019年全球糖尿病支出将达7,600亿美元，2030年将达8,250亿美元，2045年将达8,450亿美元。

主要问题

针头恐惧症：

儘管糖尿病笔使用起来很方便，但它需要使用针头，这对许多患者来说是一个大问题。注射带来的恐惧和不适可能会导致不遵守胰岛素剂量并损害血糖控制。为了解决这个问题，目前正在对无针注射器和提高患者使用糖尿病笔时的舒适度和信心的策略进行研究。

成本高：

糖尿病笔价格昂贵，尤其是新型的具有数位功能的糖尿病笔。高昂的初始购买价格和对一次性零件的持续需求可能会成为障碍，尤其是对于低收入患者而言。这些成本负担可能会限制获得重要的糖尿病治疗工具的机会并造成健康差距。为了让更多人能够使用糖尿病笔，製造商必须降低生产成本或找到生产更经济的替代品的方法。

使用者训练与教育：

正确使用胰岛素笔需要充分的训练和教育。如果您不完全瞭解如何正确使用胰岛素笔，您最终可能会服用错误的剂量或错误地註射胰岛素。确保有效和正确使用糖尿病笔需要全面的培训计划和对患者和医疗保健提供者的持续支持。

可变的胰岛素吸收：

胰岛素的吸收取决于注射部位、皮肤类型和注射技术。这些波动会对血糖控制和糖尿病治疗产生影响。要解决这个问题，需要研究改良的胰岛素配方和设计能够更持续输送胰岛素的设备。

主要趋势

无针注射的创新：

无针注射装置的进步在糖尿病笔市场越来越受欢迎。该装置旨在减少传统针头笔带来的不适和心理障碍。无针笔采用喷射和微针技术等技术，为胰岛素注射提供了更舒适、更少侵扰的选择，对害怕针头或想要更便捷解决方案的患者很有吸引力。

与数位健康平台整合：

糖尿病笔越来越多地与数位健康平台和电子健康记录（EHR）结合。这项发展将使设备和医疗保健系统之间的数据传输更加顺畅，从而改善糖尿病的监测和控制。与 EHR 的整合可以更全面地收集患者数据并改善与医疗保健提供者的沟通，从而改善整体糖尿病管理。

个人化胰岛素剂量：

人们越来越重视根据个别患者需求量身定制的胰岛素输送装置。现代糖尿病笔设计用于容纳多种类型和剂量的胰岛素，可根据每位患者的需求进行个人化治疗。这一趋势与个人化医疗的大力推动不谋而合，个人化医疗根据个人健康状况量身定制治疗方案，以提高疗效和患者满意度。

使用者体验是关键：

糖尿病笔非常重视改善使用者体验。製造商正在投资人体工学设计、直觉式介面、可调节功能等，以提高易用性。这种方法旨在使胰岛素注射尽可能简单和舒适，降低定期使用的障碍并提高患者对治疗方案的依从性。

目录

第 1 章简介

• 市场定义
• 市场区隔
• 研究方法

第 2 章执行摘要

• 主要发现 市场概况
• 市场亮点

第三章 市场概览

• 市场规模与成长潜力
• 市场趋势
• 市场推动因素
• 市场限制
• 市场机会
• 波特五力分析

第 4 章 糖尿病笔市场（按胰岛素类型）

• 速效胰岛素笔
• 基础胰岛素笔

第 5 章。

• 医院药房
• 零售药局
• 线上零售商

第 6 章 糖尿病笔市场（依病患细分）

• 1 型糖尿病患者
• 2 型糖尿病患者

第 7 章 区域分析

• 北美洲
• 美国
• 加拿大
• 墨西哥
• 欧洲
• 英国
• 德国
• 法国
• 义大利 亚太地区
• 中国
• 日本
• 印度
• 澳大利亚
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中东和非洲
• 南非
• 沙乌地阿拉伯
• 阿拉伯联合大公国

第 8 章 市场动态

• 市场推动因素
• 市场限制
• 市场机会
• COVID-19 市场影响

第 9 章 竞争格局

• 大型公司
• 市占率分析

第十章 公司简介

• Novo Nordisk（Denmark）
• Eli Lilly and Company（US）
• Sanofi（France）
• BD（Becton, Dickinson and Company）（US）
• Ypsomed Group（Switzerland）
• Merck & Co., Inc.（US）
• Boehringer Ingelheim（Germany）
• AstraZeneca plc（UK）
• Wockhardt Limited（India）
• Insulet Corporation（US）

第 11 章 市场展望与机会

• 新兴技术
• 未来市场趋势
• 投资机会

第 12 章附录

• 缩写列表
• 来源与参考文献

Diabetes Pen Market Size And Forecast

Diabetes Pen Market size was valued at USD 16.52 Billion in 2024 and is projected to reach USD 29.35 Billion by 2031 , growing at a CAGR of 7.45% from 2024 to 2031. A diabetes pen is a medical device that allows you to precisely and conveniently deliver insulin or other diabetes treatments. It usually consists of a pen-like injector with a cartridge of insulin or medicine and a disposable needle. The user selects the desired dose on the pen and administers the medication subcutaneously. Individuals with diabetes commonly utilize diabetes pens for daily insulin therapy due to their ease of use, accurate dose, and portability. They are intended to simplify diabetes care by making the injection process more user-friendly and less laborious than with standard syringes.

Diabetes pens look promising, with continual developments focused on enhancing functionality and user experience. Smart pens equipped with digital technology measure insulin doses and offer real-time data to both users and healthcare providers, allowing for better diabetes treatment.

Research into needle-free injection methods and insulin formulation advancements may increase patient comfort and adherence. The development of pens with customized features and improved connectivity to digital health systems has the potential to further change diabetes care by making it more personalized and efficient. As diabetes becomes increasingly common, these developments will play an important role in better managing the disease.

Global Diabetes Pen Market Dynamics

The key market dynamics that are shaping the global diabetes pen market include:

Key Market Drivers:

Increasing Prevalence of Diabetes:

The diabetes pen market is driven by the increasing prevalence of diabetes. The International Diabetes Federation (IDF) estimates that roughly 537 million adults (20-79 years old) will have diabetes in 2021. This figure is expected to climb to 643 million by 2030, and 783 million by 2045.

Rising Demand for Self-Administration Devices:

Diabetes pens are becoming increasingly popular because of their convenient and user-friendly nature. Research published in the Journal of Diabetes Science and Technology discovered that 71% of patients chose insulin pens to vials and syringes for insulin delivery, claiming increased quality of life and treatment satisfaction.

Increasing Healthcare Expenditure:

Rising healthcare spending, especially in developing nations, is driving the diabetes pen market. The World Health Organization (WHO) estimates that global diabetes spending hit $760 billion in 2019 and is expected to reach $825 billion by 2030 and $845 billion by 2045.

Key Challenges:

Needle Phobia:

Diabetes pens, despite their convenience, need the usage of needles, which can be a major issue for many patients. Fear or discomfort associated with injections may lead to noncompliance with insulin administration, compromising blood sugar management. To address this issue, continuous research is being conducted into needle-free injection devices and tactics for improving patient comfort and trust when using diabetic pens.

High Costs:

Diabetes pens are expensive, particularly modern kinds with digital features. The high initial purchase price and continued requirement for disposable components might be a barrier for patients, especially in low-income areas. This cost burden may restrict access to critical diabetes care tools, contributing to health inequities. To make diabetic pens more accessible to a larger audience, manufacturers must find ways to cut production costs or produce more economical alternatives.

User Training and Education:

Adequate training and education are required for the proper use of insulin pens. Inadequate understanding of how to use the device correctly can result in incorrect dose or delivery. Comprehensive training programs and continuing support for patients and healthcare providers are required to guarantee the effective and correct use of diabetes pens.

Variable Insulin Absorption:

Insulin absorption varies depending on the injection site, skin type, and injection technique. This fluctuation can have an impact on blood glucose control and diabetes treatment in general. To overcome this issue, research into refining insulin formulations and designing devices for more constant insulin delivery is required.

Key Trends:

Needle-Free Innovations:

Advancements in needle-free injection devices are gaining popularity in the diabetes pen market. The devices are intended to decrease the discomfort and psychological hurdles associated with traditional needle-based pens. Needle-free pens, which use technologies such as jet injection or microneedle technology, provide a more comfortable and less intrusive option for insulin delivery, making them appealing to patients who are afraid of needles or who want a more convenient solution.

Integration with Digital Health Platforms:

Diabetes pens are becoming more linked with digital health platforms and electronic health records (EHRs). This development allows for more smooth data transmission between devices and healthcare systems, which improves diabetes monitoring and control. Integration with EHRs enables more thorough gathering of patient data, improved contact with healthcare providers, and better overall diabetes management.

Personalized Insulin Delivery:

There is an increasing emphasis on insulin administration devices that are tailored to individual patient needs. Modern diabetic pens are intended to accommodate a variety of insulin kinds and dosages, allowing for personalized therapy depending on individual patient needs. This tendency is consistent with the larger push toward personalized medicine, in which therapies are tailored to individual health profiles, increasing efficacy and patient satisfaction.

Focus on User Experience:

Diabetes pens place a great emphasis on improving the user experience. Manufacturers are investing in ergonomic designs, intuitive interfaces, and adjustable features to improve usability. This approach tries to make insulin administration as simple and comfortable as feasible, lowering barriers to regular use and improving patient adherence to treatment regimens.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Diabetes Pen Market Regional Analysis

Here is a more detailed regional analysis of the global diabetes pen market:

North America:

North America holds the lead in the diabetic pen market due to several relevant reasons. The high prevalence of diabetes in the region, along with a well-developed healthcare infrastructure and a strong presence of large pharmaceutical corporations, has led to the widespread use of insulin pens. The complex healthcare system in North America promotes the incorporation of advanced diabetes management systems, resulting in a large market for these goods. The concentration of prominent pharmaceutical companies has fueled innovation in diabetes pen technology, resulting in a wide selection of devices adapted to different patient needs.

The rising prevalence of diabetes in North America is a major driver of market expansion. According to the CDC, around 37.3 million Americans had diabetes in 2021, with a projected increase to 60.6 million by 2060. Diabetes has a significant economic burden, with direct medical expenses estimated at USD 374 Billion per year. This highlights the need for effective treatment tools such as insulin pens. Technological improvements drive market expansion. This expansion is being driven by greater adoption of connected devices and a demand for more personalized diabetes care options.

Asia Pacific:

The Asia Pacific diabetes pen market is rapidly expanding, owing to the high prevalence of diabetes in densely populated countries such as China and India. The rising prevalence of diabetes, combined with increased awareness and access to healthcare, is driving growing demand for insulin pens. Insulin pens are gaining popularity as a cost-effective and user-friendly alternative to standard injectable procedures. This shift to insulin pens is helped by the region's increasing healthcare infrastructure, which encourages the widespread use of modern diabetes control tools.

The high prevalence of diabetes in Asia Pacific is a key driver of market growth. The International Diabetes Federation (IDF) forecasts that 206 million adults in the Western Pacific region will have diabetes in 2021, with this total expected to climb to 260 million by 2045. China alone had 140.9 million cases in 2021, with a projected increase to 174.4 million by 2045. Diabetes's economic impact in the region, which is expected to be USD 241 Billion in 2021, highlights the need for efficient and cost-effective management solutions. The growing diabetic population, as well as the increased adoption rates of insulin pens, show the region's growing demand for effective diabetes care options.

Global Diabetes Pen Market: Segmentation Analysis

The Global Diabetes Pen Market is Segmented on the basis of Product Type, Distribution Channel, Patient Population, And Geography.

Diabetes Pen Market, By Product Type

• Disposable
• Reusable

Based on Product Type, the market is fragmented into Disposable and Reusable. The disposable segment of the diabetes pen market dominates due to its simplicity and ease of usage. Many patients prefer disposable pens due to they are simple to use and eliminate the need for cleaning and refilling. The reusable category is rapidly expanding. Reusable pens save money over time and are becoming increasingly popular as patients look for more environmentally friendly and cost-effective solutions. The increased preference for reusable pens indicates a trend toward long-term value and environmental conscience, which is fueling their rapid market growth.

Diabetes Pen Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Retailers

Based on Distribution Channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Retailers. Retail pharmacies are the dominant segment in the diabetic pen market due to their widespread accessibility and established presence, which allows patients to acquire diabetes pens on demand. Online merchants are the fastest-growing segment, driven by the expanding popularity of e-commerce and the convenience of online buying. Online platforms provide greater product selections, home delivery, and often cheaper pricing, attracting an increasing number of customers looking for a more convenient and flexible purchase experience.

Diabetes Pen Market, By Patient Population

• Type 1 Diabetes
• Type 2 Diabetes

Based on Patient Population, the market is segmented into Type 1 Diabetes and Type 2 Diabetes. The Type 2 Diabetes segment is dominating the diabetes pen market due to its higher prevalence than Type 1 diabetes. As Type 2 diabetes becomes more prevalent, there is an increased demand for diabetes care solutions among these individuals. Type 1 Diabetes is the fastest-growing group, owing to increased awareness and breakthroughs in treatment technologies. The rising emphasis on personalized insulin delivery systems, as well as diabetes care advancements, are fueling the Type 1 diabetes segment's rapid growth.

• Diabetes Pen Market
• , By Geography
• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Geography, the Global
• Diabetes Pen Market
• is classified into North America, Europe, Asia Pacific, and the Rest of the World. North America dominates the diabetic pen market, owing to its high prevalence of diabetes, modern healthcare infrastructure, and powerful pharmaceutical businesses. The Asia Pacific area is growing fastest, owing to rising diabetes incidence, more awareness, and improved healthcare access in nations such as China and India. This region's significant population and rapid economic development are driving up demand for diabetes pens, making it a viable market in the future.

Key Players

• The "Global
• Diabetes Pen Market
• " study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Novo Nordisk, Eli Lilly and Company, Sanofi, BD (Becton, Dickinson and Company), Ypsomed Group, Merck & Co., Inc., Boehringer Ingelheim, AstraZeneca plc, Wockhardt Limited, and Insulet Corporation.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Diabetes Pen Market
• Recent Developments
• In September 2023, Eli Lilly announced a 70% price reduction for its most popular insulins and expanded its Insulin Value Program. The program now limits patients' out-of-pocket expenses to $35 per month. To help patients even more, Eli Lilly implemented a $35 monthly cap on insulin-related medications. This approach attempts to keep patients from experiencing financial hardship as a result of high insulin prices.
• In October 2022, Novo Nordisk announced the completion of the Forma Therapeutics acquisition.
• In December 2022, Sanofi and Innate Pharma will expand their relationship in oncology with natural killer cell therapies.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Diabetes Pen Market, By Insulin Type

• Rapid-Acting Insulin Pens
• Basal Insulin Pens

5. Diabetes Pen Market, By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Retailers

6. Diabetes Pen Market, By Patient Population

• Type 1 Diabetes Patients
• Type 2 Diabetes Patients

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Novo Nordisk (Denmark)
• Eli Lilly and Company (US)
• Sanofi (France)
• BD (Becton, Dickinson and Company) (US)
• Ypsomed Group (Switzerland)
• Merck & Co., Inc. (US)
• Boehringer Ingelheim (Germany)
• AstraZeneca plc (UK)
• Wockhardt Limited (India)
• Insulet Corporation (US)

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References